J
James D. Neaton
Researcher at University of Minnesota
Publications - 352
Citations - 68183
James D. Neaton is an academic researcher from University of Minnesota. The author has contributed to research in topics: Risk factor & Blood pressure. The author has an hindex of 101, co-authored 331 publications receiving 64719 citations. Previous affiliations of James D. Neaton include University of Pittsburgh & Medical Research Council.
Papers
More filters
Journal ArticleDOI
Characterization of Ebola Virus-Associated Eye Disease.
Allen O. Eghrari,Rachel Bishop,Robin Demi Ross,Bionca Davis,Jemma Larbelee,Fred Amegashie,Robert Dolo,S. Grace Prakalapakorn,Catherine Gaisie,Catherine Gargu,Yassah Sosu,Jennie Sackor,Precious Z. Cooper,Augustine Wallace,Ruth Nyain,Maima Gray,Famatta Kamara,Bryn M. Burkholder,Christopher J. Brady,Vincent Ray,Kirstin L. Tawse,Ian Y L Yeung,James D. Neaton,Elizabeth S. Higgs,H. Clifford Lane,Cavan S. Reilly,Michael C. Sneller,Mosoka Fallah +27 more
TL;DR: In this paper, a baseline cross-sectional analysis of survivors of Ebola virus disease and their close contacts was conducted within PREVAIL III, a 5-year, longitudinal cohort study.
Journal ArticleDOI
Pilot study of vascular health in survivors of osteosarcoma.
Daniel A. Mulrooney,Daniel A. Mulrooney,Kirsten K. Ness,Sujuan Huang,Anna Solovey,Robert P. Hebbel,James D. Neaton,Denis R. Clohisy,Aaron S. Kelly,Joseph P. Neglia +9 more
TL;DR: Cardiovascular‐related toxicities have been reported among survivors of osteosarcoma.
Journal ArticleDOI
Biomarkers and Electrocardiographic Evidence of Myocardial Ischemia in Patients With Human Immunodeficiency Virus Infection
Mihir Gupta,Christopher J. Miller,Jason V. Baker,Jason V. Baker,Jason Lazar,Johannes R. Bogner,Alexandra Calmy,Elsayed Z. Soliman,James D. Neaton +8 more
TL;DR: Elevated biomarker levels and ECG abnormalities indicating myocardial ischemia might reflect different risk pathways for cardiovascular disease, and higher levels of hsCRP, IL-6, and D-dimer were not associated with ischemicECG abnormalities.
Journal ArticleDOI
Risk factors for low CD4+ count recovery despite viral suppression among participants initiating antiretroviral treatment with CD4+ counts >500 cells/mm3: findings from the Strategic Timing of AntiRetroviral Therapy (START) trial.
Jeffrey A. Boatman,Jason V. Baker,Sean Emery,Hansjakob Furrer,David M. Mushatt,Dalibor Sedláček,Jens D Lundgren,James D. Neaton +7 more
TL;DR: Low CD4+ recovery is frequent among participants starting ART at highCD4+ counts, and at higher HIV RNA levels, the odds of low CD4- recovery were higher among those with lower vs. higher screening CD4+.